Statistical Approaches to Establishing Bioequivalence

2 December 2022 – the FDA published draft guidance on statistical approaches to establishing bioequivalence for industry.

Requirements for submitting bioavailability (BA) and bioequivalence (BE) data in investigational new drugs (INDs), new drug applications (NDAs), abbreviated new drug applications (ANDAs), and supplements; the definitions of BA and BE; and the types of in vitro and in vivo studies that are appropriate to measure BA and establish BE are set forth in part 320 (21 CFR part 320). This guidance provides recommendations on how to meet provisions of part 320 for all drug products.

Read more online 
Copyright Widler & Schiemann AG 2022. All Rights Reserved. /